Clinical Pipeline
Advancing innovative therapies through clinical development
PRX-P4-003 Clinical Development Program
Building on the solid scientific foundation detailed in our Science section, we are advancing PRX-P4-003 through a strategic clinical development pathway for multiple indications with significant unmet needs. Our clinical program is designed to efficiently generate the data needed for regulatory approval while addressing key questions about safety, efficacy, and optimal dosing.
Strategic Partnership Opportunity
Praxis Bioresearch is seeking strategic partners to accelerate the clinical entry of PRX-P4-003, a clinical-stage new chemical entity (NCE) that combines structural novelty with the de-risking benefit of a well-characterized active moiety. The asset is Phase 1-ready with FDA IND clearance, GMP drug product available for clinical use, and patent protection expected into the early 2040s, including potential patent term extension (PTE).
PRX-P4-003 delivers the active isomer of fencamfamine — a DEA-listed Schedule IV substance with several decades of prior clinical safety experience, but never previously approved for ADHD or apathy indications. Authoritative records (DrugBank, PubChem, WHO ECDD) confirm fencamfamine's historical commercial exit reflected a manufacturer portfolio decision, not safety, dependence, or abuse concerns.
- Status: FDA IND Cleared; GMP product available
- Pharmacology: Differentiated balanced dopamine and norepinephrine engagement, designed for stable daily efficacy
- Regulatory category: Schedule IV pathway potential — a broader-access tier than current first-line stimulants
- IP Position: Patent protection expected into the early 2040s, including potential PTE, with 100% in-house IP ownership
Qualified parties are invited to engage in technical due diligence and request access to partnership materials, including the PRX-P4-003 Virtual Data Room.
Request Partnership AccessProgram Focus by Indication
- ADHD: Phase 1-ready stimulant alternative with potential Schedule IV positioning.
- Apathy in Alzheimer's Disease: IND-cleared program targeting a major unmet neuropsychiatric need.
- Apathy in Frontotemporal Dementia: Expansion opportunity for motivational impairment in neurodegeneration.
- Traumatic Brain Injury: Potential development path for cognitive and motivational deficits post-TBI.
Platform Potential
PRX-P4-003's dopamine and norepinephrine modulation mechanism, combined with its abuse-resistant prodrug design, creates strategic optionality across multiple high-value CNS indications where current options are limited or where no FDA-approved therapy exists.
- Lead programs: ADHD and apathy in Alzheimer's Disease — large-market and first-in-class opportunities
- Adjacent CNS programs: apathy in Frontotemporal Dementia and post-TBI deficits — orphan and high-unmet-need indications
- Strategic optionality: A single Phase 1 dataset is expected to support multiple downstream indication pathways
Praxis is open to indication-specific licensing, regional partnerships, and broader strategic collaborations.
Recent Milestones
- IND CLEARED by FDA recently for initiating Phase 1 Studies
- GMP API and drug product successfully developed and available for Phase 1 and Phase 2 clinical testing
- SUCCESSFUL microdose PK study in HUMANS
Development Impact Highlights
PRX-P4-003 aims to address significant unmet needs affecting millions of patients worldwide. With approximately 70% of current ADHD treatments being stimulant-based, our innovative approach focuses on improving patient access and outcomes through potential Schedule IV classification. Our development pipeline prioritizes patient safety and treatment accessibility, particularly targeting the challenges faced by the estimated 379 million individuals affected globally, including 144-160 million children and 201.5 million adults with ADHD, along with 22-34 million Alzheimer's Disease patients experiencing apathy.
Sources: Global ADHD prevalence based on WHO and CDC data; Apathy in AD statistics from Alzheimer's Association and clinical studies.
Competitive Advantages
PRX-P4-003 offers several key advantages over existing therapies:
Schedule IV Stimulant Potential
PRX-P4-003 is based on fencamfamine, an established Schedule IV stimulant, and has been additionally protected against abuse by restricting its activation only by the oral route, thereby reducing abuse potential. This could position it as the first Schedule IV stimulant for ADHD, offering improved safety, efficacy and easier access than current Schedule II stimulants. Fencamfamine remains DEA-listed as Schedule IV — a category with lower abuse potential than Schedule II stimulants.
Balanced Mechanism
A differentiated balanced dopamine and norepinephrine profile designed to deliver stable, all-day efficacy with potentially improved tolerability versus established stimulant classes. For more details on the scientific foundations and mechanisms of action, visit our Science page.
Built-in Abuse Deterrence
Gut-specific activation mechanism prevents misuse through intranasal or injection routes, potentially qualifying for Schedule IV classification.
Established Safety Foundation
Built on the active isomer of fencamfamine, with several decades of clinical use. Authoritative records (DrugBank, PubChem, WHO ECDD) confirm its historical commercial exit reflected manufacturer portfolio strategy, not safety, dependence, or abuse.
Full In-House Development
Developed entirely in-house from discovery through clinical stages, providing complete IP ownership, deep scientific insight, and full strategic control over development and commercialization.
Once-Daily Dosing
Extended duration of action (approximately 15 hours) enables convenient once-a-day therapy.